Masouridi-Levrat, Stavroula http://orcid.org/0000-0001-7502-5454
Olavarria, Eduardo
Iacobelli, Simona
Aljurf, Mahmoud
Morozova, Elena http://orcid.org/0000-0002-9605-485X
Niittyvuopio, Riitta
Sengeloev, Henrik
Reményi, Peter
Helbig, Grzegorz
Browne, Paul
Ganser, Arnold
Nagler, Arnon http://orcid.org/0000-0002-0763-1265
Snowden, John A. http://orcid.org/0000-0001-6819-3476
Robin, Marie http://orcid.org/0000-0003-1388-9876
Passweg, Jakob
Van Gorkom, Gwendolyn
Wallet, Hélène Labussière
Hoek, Jennifer
Blok, Henric-Jan
De Witte, Theo
Kroeger, Nicolaus
Hayden, Patrick http://orcid.org/0000-0003-1374-4503
Chalandon, Yves http://orcid.org/0000-0001-9341-8104
Agha, Ibrahim Yakoub http://orcid.org/0000-0003-4524-8782
Article History
Received: 21 February 2021
Revised: 17 August 2021
Accepted: 14 September 2021
First Online: 1 October 2021
Competing interests
: YC: Novartis, BMS, Pfizer, Incyte: advisory board; Novartis, BMS: travel grant. IYA: received honoraria from Novartis. JAS: none directly related to this project but otherwise received speaker fees; Jazz, Mallinckrodt, Janssen, Gilead; advisory board; Medac, and clinical trial IDMC membership; Kiadis. The remaining authors declare no competing interests.